Esquistosomiasis mansónica / Schistosomiasis masoni

Se presenta el caso clínico de un paciente de 10 años de edad, quien asistió al puesto médico de Santa Johana, municipio de Itamarandiba, estado brasileño de Minas Gerais, acompañado de su madre, por presentar dolor abdominal de tipo cólico, con deposiciones diarreicas mezcladas con sangre y falta de apetito, además ligera palidez cutaneomucosa, lo cual se correspondían con una esquistosomiasis mansónica. Se le realizaron los exámenes pertinentes y se le indicó el tratamiento oportuno, de manera que el niño evolucionó favorablemente

The case report of a 10 years patient is presented who attended Santa Johana doctor´s office, Itamarandiba municipality, Minas Gerais Brazilian state, accompanied by his mother, due to abdominal pain of colic type, with diarrhea mixed with blood and loss of appetite, also a light mucouscutaneous paleness, which corresponded to a schistosomiasis mansoni. The pertinent exams were carried out and the appropriate treatment was indicated, so that the boy had a favorable clinical course

Prolonged use of nimotuzumab in children with central nervous system tumors: safety and feasibility.

Primary brain tumors constitute the most frequent solid tumor of childhood. High expression of the epidermal growth factor receptor (EGFR) protein has been associated with tumor progression and enhanced tumorigenicity in adult and children gliomas. Nimotuzumab is a humanized antibody that targets the EGFR and has proven efficacy in adult and children gliomas. To provide a new therapeutic option for patients with active, poor prognosis central nervous system (CNS) tumors and to evaluate the feasibility and safety of long-term nimotuzumab therapy in children with diverse CNS tumors, an expanded access program was launched at the Juan Manuel Marquez hospital. Patients were required to be 18 or younger and have one CNS tumor: low-grade glioma (LGG) or high-grade glioma (HGG), brainstem glioma (BSG), ependymoma or primitive neuroectodermal tumor (PNET), and a Lansky or Karnofsky performance status ≥40. Treatment consisted of weekly nimotuzumab administered at 150 mg/m(2) for 12 weeks, continuing every 14 days in the absence of severe condition worsening or unacceptable toxicity. Nimotuzumab was administered alone or in combination with radiotherapy, chemotherapy, or both, depending on the tumor type, stage, and previous treatment. Eighty-eight patients, 39 with BSG, 25 with HGG, 9 with progressive LGG, 9 with anaplastic ependymomas, and 6 with other tumor types, including PNET, neuroblastoma, meduloblastoma, and thalamic tumors, were treated with the antibody. The mean number of nimotuzumab doses was 36, from 1 to 108. The most frequent adverse events were mild to moderate skin rash, mucositis, vomiting, seizures, hypothermia, hyperthermia, and paleness. One patient had a grade 3 mucositis, while the other had a grade 3 bleeding on surgery. Sixteen children stopped treatment after at least 2 years with stable disease, partial or complete response. All children were able to maintain the best response achieved on treatment after a 3-year interruption. In summary, this study shows the feasibility of very prolonged administration of nimotuzumab together with the lack of rebound effect after treatment cessation.

Complexation of arsenite with humic acid in the presence of ferric iron.

In the presence of iron (Fe), dissolved organic matter (DOM) may bind considerable amounts of arsenic (As), through formation of Fe-bridged As-Fe-DOM complexes and surface complexation of As on DOM-stabilized Fe-colloids (collectively referred to as As-Fe-DOM complexation). However, direct (e.g., chromatographic and spectroscopic) evidence and fundamental kinetic and stability constants have been rarely reported for this As-Fe-DOM complexation. Using a size exclusion chromatography (SEC)-UV-inductively coupled plasma mass spectrometry (ICP-MS) technique, arsenite (As(III))-Fe-DOM complexation was investigated after adding As(III) into the priorly prepared Fe-DOM. A series of evidence, including coelution of As, Fe, and DOM from the SEC column and coretention of As, Fe, and DOM by 3 kDa MWCO centrifugal filtration membrane, demonstrated the occurrence of As(III)-Fe-DOM complexation. The kinetic data of As(III)-Fe-DOM complexation were well described by a pseudofirst order rate equation (R(2) = 0.95), with the rate constant (k') being 0.17 ± 0.04 1/h. Stability of As(III)-Fe-DOM complexation was characterized by apparent stability constant (K(s)) derived from two-site ligand binding model, with log K(s) ranging from 4.4 ± 0.2 to 5.6 ± 0.4. Considering the kinetics (within hours) and stability (similar to typical metal-humates) of As(III)-Fe-DOM complexation, this complexation needs to be included when evaluating As mobility in Fe and DOM rich environments.